Clinical Trials Sponsored by Nordic Nanovector

Total 2619 results

Nordic Nanovector

Withdrawn

Dosimetry Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-02)

Non-Hodgkin Lymphoma

Germany
Nordic Nanovector

Completed

Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05)

Refractory Diffuse Large B-Cell Lymphoma | Relapsed, Diffuse Large B-cell Lymphoma

Spain, United Kingdom, Italy, United States, Germany
Nordic Nanovector
ICON Clinical Research

Completed

A Phase 1/2 Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-01)

Follicular Lymphoma | Non-Hodgkin Lymphoma

United States, Korea, Republic of, Australia, Austria, Belgium, Canada, Croatia, Czechia, Denmark, Finland, France, Hungary, Ireland, Israel, Italy, Netherlands, Norway, Poland, Singapore, Spain, Sweden, Switzerland, Turkey, United Kingdom
Nordic Nanovector
ICON Clinical Research

Completed

Study of Safety and Efficacy of Betalutin and Rituximab in Patients With FL (LYMRIT-37-07)

Follicular Lymphoma | Non Hodgkin Lymphoma | Relapsed Follicular Lymphoma

Czechia, Norway
Bavarian Nordic

Recruiting

Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination

Chikungunya Virus Infection

United States
Bavarian Nordic

Completed

A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer

Solid Metastatic Tumor

United States
Bavarian Nordic

Completed

A Phase II Trial to Compare a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects

Smallpox

United States
Bavarian Nordic

Completed

Special Access Program IMVAMUNE®

Vaccination

United States
Bavarian Nordic

Completed

A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer (Prospect)

Prostate Cancer Metastatic

United States, Spain, Germany, Netherlands, Belgium, United Kingdom, Australia, Denmark, France, Canada, Israel, Russian Federation, Puerto Rico, Estonia, Poland, Iceland
Bavarian Nordic

Completed

A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Metastatic Breast Cancer

Breast Cancer

United States
Bavarian Nordic

Withdrawn

RSV-MVA-BN Vaccine Phase I Trial, Intranasal Application in Adults.

Respiratory Syncytial Virus Infections
Bavarian Nordic

Completed

Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Recombinant MVA BN® RSV Vaccine

Respiratory Syncytial Virus Infections

United States
Bavarian Nordic

Completed

Phase I Safety Study of a Recombinant MVA HIV Multiantigen Vaccine in HIV-infected Subjects

HIV Infections

United States
Bavarian Nordic

Completed

Take Rate, Immunogenicity and Safety of Elstree-BN Smallpox Vaccine in Healthy Vaccinia-Naive Subjects

Smallpox

Germany
Bavarian Nordic

Completed

Study on Safety, Tolerability and Immunogenicity of an MVA Vaccine Administered to Healthy Subjects

Smallpox

Germany
Bavarian Nordic

Active, not recruiting

TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer

Chordoma | HER2-positive Breast Cancer | HER2-positive Gastric/Gastroesophageal Junction Cancer

United States
Bavarian Nordic

Completed

ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2

COVID-19 Disease

United States, Denmark, Belgium
Bavarian Nordic

Completed

MVA-BN-RSV Vaccine Trial

Respiratory Syncytial Virus Infections

United States, Germany
Bavarian Nordic

Completed

BN Brachyury and Radiation in Chordoma

Chordoma

United States
Bavarian Nordic

Completed

CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer

Bladder Cancer

United States
Bavarian Nordic

Completed

Safety and Tolerability Trial (MVA-BN-Brachyury/FPV-Brachyury)

Safety Issues

United States
Bavarian Nordic

Completed

A Trial of CV301 in Combination With Anti-PD-1 Therapy in Subjects With Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer (NSCLC)

United States
Bavarian Nordic

Completed

A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Breast Cancer After Adjuvant Therapy

Breast Cancer

United States
Bavarian Nordic

Completed

A Safety Trial of MVA-BN®-PRO in Men With Androgen-Insensitive Prostate Cancer (BNIT-PR-001)

Androgen-insensitive Prostate Cancer

United States
Bavarian Nordic

Completed

A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects

Smallpox

United States
Bavarian Nordic

Completed

Safety and Immunogenicity Study of Recombinant Modified Vaccinia Virus Ankara (MVA) Virus to Treat HIV Infection

HIV Infections

Germany
Bavarian Nordic

Completed

Study to Evaluate Safety, Dose Response and Immunogenicity of the Measles Vaccine MVA mBN85B in Healthy Children Aged 6 Months to 6 Years

Measles

South Africa
Bavarian Nordic

Completed

Phase 2a Study of MVA-BN-RSV Vaccination and RSV Challenge in Healthy Adults

RSV Infection

United Kingdom
Bavarian Nordic

Active, not recruiting

ABNCoV2 Vaccine in SARS-CoV-2 (COVID-19) Seronegative and Seropositive Adult Subjects

COVID-19 Disease

Germany
Bavarian Nordic

Completed

RSV-MVA-BN Vaccine Phase II Trial in ≥ 55 Year Old Adults

Respiratory Syncytial Virus Infections

United States
Bavarian Nordic

Completed

Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection

Smallpox

United States, Puerto Rico
Bavarian Nordic

Completed

A Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects

Smallpox

United States
Nordic Myeloma Study Group
Nordic Cancer Union

Completed

Pamidronate Prophylaxis in Multiple Myeloma 30 mg/Month Versus 90 mg/Month

Multiple Myeloma

Denmark, Norway, Sweden
Viiral Nordic AB

Completed

A Post-Market Clinical Follow-up Investigation to Verify Performance and Safety of Viiral®Nasal Spray in Subjects With Dry Nose Symptoms

Rhinitis Sicca

Sweden
Nordic Pharma SAS

Unknown

Prevention of Adhesions During Celioscopy for Endometriosis. Impact of the Use of Anti-adhesion Treatment on Clinical Signs and Fertility at One Year (ENDHY)

Endometriosis, Adhesive

France
Nordic Pharma SAS

Completed

Spinal Versus General Anesthesia for Ambulatory Anesthesia (BAG)

Spinal Anesthesia | Outpatient Surgery | Short General Anesthesia

France
Nordic Pharma SAS

Terminated

Clinical Study Comparing the New Immunosuppressive Drug Gusperimus With the Conventional Treatment in Wegener's Granulomatosis (SPARROW)

Wegeners Granulomatosis

Czech Republic
Nordic Pharma SAS

Completed

Impact of Chloroprocaine (CLOROTEKAL®) on Eligibility for Discharge From Hospital After Outpatient Surgery (CLOCK)

Spinal Anesthesia | Outpatient Surgery

France
Nordic MDS Group

Unknown

The Efficacy of Azacitidine +/- Lenalidomide in High-risk Myelodysplastic Syndrome (MDS)and Acute Myeloid Leukemia (AML) With Del(5q).

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

Sweden
Nordic Pharma SAS

Active, not recruiting

Therapeutic Strategy Associated With bDMARDs or tsDMARDs in Rheumatoid Arthritis and Psoriatic Arthritis (STRATEGE2)

Rheumatoid Arthritis | Psoriatic Arthritis

France
Nordic Pharma SAS

Completed

Treatment Adherence to Injectable Methotrexate in Rheumatoid Arthritis (APRim)

Rheumatoid Arthritis

France
Nordic MDS Group

Unknown

Individual Molecular MRD Monitoring for MDS Patients After Allo-SCT

MDS | SCT | MRD

Denmark, Norway, Sweden
Nordic Pharma SAS

Completed

Comparison of Compliance and Evolution of Functional Capacity of Patients With Rheumatoid Arthritis Treated by Methotrexate Either by Auto-injector or by Conventional Sub-cutaneous Syringe (Self-i)

Arthritis, Rheumatoid

France
Nordic Pharma SAS

Completed

Efficacy of Mifepristone - Prostaglandin Analogue Combination in Medical Termination of Pregnancy Beyond 7 Weeks of Amenorrhea

Medical Termination of Pregnancy

France
Nordic Pharma SAS

Completed

Therapeutic Strategy in Patients Treated With Methotrexate for Rheumatoid Arthritis (STRATEGE)

Rheumatoid Arthritis

France
Nordic Pharma SAS

Completed

Feasibility of a Self-performed Urinary Test for the Follow-up on Medical Abortion

Abortion; Attempted, Medical

France
Nordic Drugs AB

Completed

Efficacy and Safety Study of a Medical Device (KULIST)to Treat Perianal Fistulas

Perianal Fistulas

Sweden
Nordic Lymphoma Group

Completed

Trial of Idelalisib in Patients With Relapsed Diffuse Large B-cell Lymphoma (ILIAD)

Diffuse Large B Cell Lymphoma

Denmark, Sweden
Nordic Lymphoma Group

Active, not recruiting

Venetoclax, Lenalidomide and Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma (VALERIA)

Relapsed Non Hodgkin Lymphoma

Norway, Sweden, Finland, Denmark
Nordic MDS Group

Completed

Evaluation of Azacitidine in Transfusion Dependent Patients With Low-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)

Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome

Denmark, Norway, Sweden

3

Subscribe